Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 22:4:222.
doi: 10.1186/1752-1947-4-222.

A rare case of uterine leiomyosarcoma: a case report

Venkata Sujatha Vellanki  1 , Meghana Rao, Chinna Babu Sunkavalli, Rao N Chinamotu, Shailaja Kaja
Affiliations

A rare case of uterine leiomyosarcoma: a case report

Venkata Sujatha Vellanki et al. J Med Case Rep. .

Abstract

Introduction: Malignant change in a leiomyoma or uterine fibroid is termed leiomyosarcoma. It arises from smooth muscle of the uterus and is a rare tumor that accounts for 2% to 5% of all uterine malignancies. Very few cases are reported in the literature. Our patient did not have any history of genital bleeding, which is the usual presentation in uterine sarcoma. We report an original case report of an unusual presentation of this rare tumor arising from the uterus.

Case presentation: A 40-year-old nulliparous woman of South Indian origin presented with a mass in her abdomen for one year with a rapid increase in size over the previous three months. Tumor marker CA-125 was raised, and a computed tomography scan showed a mass arising from the pelvis. An exploratory laparotomy was performed and the histopathology report confirmed the diagnosis of uterine leiomyosarcoma.

Conclusion: Because of their rarity, uterine sarcomas are not suitable for screening. Diagnosis is by histopathologic examination and surgery is the only treatment. The prognosis for women with uterine sarcoma primarily depends on the extent of disease at the time of diagnosis and the mitotic index.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The uterus with a pedunculated tumor.
Figure 2
Figure 2
A lobulated mass arising from the uterine fundus.
Figure 3
Figure 3
The uterus, cervix, bilateral fallopian tubes and ovaries and mass from fundus.
Figure 4
Figure 4
Cut sections of the uterus and the tumor.
Figure 5
Figure 5
Microscopic examination showing a cellular tumor arranged in interlacing bundles of spindle cells with elongated hyperchromatic nuclei and nuclear pleomorphism.
See this image and copyright information in PMC

References

    1. Forney JP, Buschbaum HJ. Classifying staging and treating uterine sarcomas. Contemporary Ob Gyn. 1981;18(3):47. 50, 55-56, 61-62, 64, 69.
    1. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres ALERT Group Assessment of Liver and Endometrial Cancer Risk Following Tamoxifen. Lancet. 2000;356:881–887. doi: 10.1016/S0140-6736(00)02677-5. - DOI - PubMed
    1. Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, Runowicz CD. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002;20:2758–2760. - PubMed
    1. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasmam WT, Currie JL, Yordan E, Brady MF. Prognostic factors in early stage uterine sarcoma. A Gynaecologic Oncology group study. Cancer. 1993;71(4):1702–1709. - PubMed
    1. Evans HL, Chawla SP, Simpson C, Finn KP. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer. 1988;62(10):2239–2247. doi: 10.1002/1097-0142(19881115)62:10<2239::AID-CNCR2820621028>3.0.CO;2-Y. - DOI - PubMed